Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Inflammatory myofibroblastic tumour (IMT), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
How long to continue ALK inhibition in children with complete response, and whether surgery after response can allow stopping.
The fusion-negative minority: RNA sequencing to find drivers.
Rare aggressive epithelioid variants that develop resistance mutations to sequential ALK inhibitors.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 9 changes by month →When this page itself was last checked or edited.
FDA approved crizotinib (Xalkori, Pfizer Inc.) for adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory anaplastic lymphoma kinase (ALK)-positive myofibroblastic tumors (IMT).
ALK-positive inflammatory myofibroblastic tumour
FDA, 14 July 2022, adults and children aged 1 year and older.
Schöffski and colleagues, Lancet Respir Med: high response rate in ALK-positive IMT.
In relapsed ALK-positive ALCL, overall response 83 and 90 per cent at the two doses, with complete responses in 21 of 26.